Strikingly, growing evidence supports the role of LRRK2 in inflammation and the onset of inflammatory diseases such as Crohn’s disease, an inflammatory Bowel disease (IBD) (Hui et al., 2018) and patients with IBD are more likely to develop PD (Villumsen et al., 2019). This evidence concerns the gene LRRK2 and inflammatory bowel disease.